Education
About Us
Working with TipRanks
Follow Us
IBRN - ETF AI Analysis
Top Page
iShares Neuroscience and Healthcare ETF (IBRN)
Rating:53Neutral
Price Target:
$30.00
Positive Factors
Strong Year-to-Date Performance
The ETF has delivered solid returns year-to-date, indicating strong momentum in its holdings.
Focused Healthcare Exposure
With over 91% of assets in healthcare, the fund targets a high-growth sector with long-term potential.
Reasonable Expense Ratio
The ETF charges a moderate fee compared to many specialized funds, making it cost-effective for investors.
Negative Factors
Over-Concentration in Healthcare
The fund's heavy focus on healthcare limits diversification and exposes investors to sector-specific risks.
Underperforming Holdings
Several top holdings, including Biogen and Catalyst Pharma, have shown weak or negative performance recently.
Limited International Exposure
With over 81% of assets in U.S. companies, the ETF offers minimal diversification across global markets.
IBRN vs. SPDR S&P 500 ETF (SPY)
AUM4.36M
RegionGlobal
Expense Ratio0.47%
Beta1.11
IssueriShares
Inception DateAug 24, 2022
Dividend Yield0.34%
Asset ClassEquity
Index TrackedNYSE FactSet Global Neuro Biopharma and MedTech Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume565
30 Day Avg. Volume751
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
42.43Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering61
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
IBRN Summary
The iShares Neuroscience and Healthcare ETF (IBRN) is a fund that focuses on companies in the health care sector, particularly those working on cutting-edge neuroscience, pharmaceuticals, and biotechnology. It tracks the NYSE FactSet Global Neuro Biopharma and MedTech Index, giving investors exposure to innovative firms like Biogen and Catalyst Pharma, which are leaders in neurological treatments. This ETF could be appealing for someone looking to invest in medical advancements and diversify their portfolio with health care stocks. However, new investors should know that the fund’s performance is closely tied to the health care sector, which can be volatile and sensitive to regulatory changes.
How much will it cost me?The iShares Neuroscience and Healthcare ETF (IBRN) has an expense ratio of 0.47%, which means you’ll pay $4.70 per year for every $1,000 invested. This is slightly higher than average because it’s a sector-focused fund that requires more active management to target specific companies in the neuroscience and healthcare fields.
What would affect this ETF?The iShares Neuroscience and Healthcare ETF (IBRN) could benefit from growing global demand for advanced neurological treatments and breakthroughs in biotechnology, as well as increased funding for health care innovation. However, it may face challenges from regulatory hurdles in drug approvals, potential economic slowdowns impacting research budgets, and competition within the pharmaceutical and biotech sectors. Its global exposure and focus on cutting-edge companies provide opportunities but also expose it to risks tied to international market conditions.
IBRN Top 10 Holdings
The iShares Neuroscience and Healthcare ETF (IBRN) is heavily concentrated in the health care sector, with a global mix of companies driving innovation in neuroscience and life sciences. Biogen and Axsome Therapeutics are steady performers, benefiting from strong revenue growth and strategic R&D efforts, though profitability concerns linger. Scholar Rock and Praxis Precision Medicines are lagging, weighed down by financial challenges and ongoing losses, despite promising pipelines. Meanwhile, Centessa Pharmaceuticals shows mixed signals, with recent gains offset by funding concerns. Overall, the fund’s focus on cutting-edge biotech and pharma creates both opportunities and risks for investors.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Praxis Precision Medicines | 4.97% | $217.26K | $4.25B | 127.92% | 56 Neutral | |
| PTC Therapeutics | 4.74% | $207.21K | $6.30B | 81.52% | 74 Outperform | |
| Argenx Se | 4.35% | $190.13K | $56.75B | 51.66% | 79 Outperform | |
| Scholar Rock Holding | 4.29% | $187.89K | $4.10B | 34.39% | 50 Neutral | |
| Biogen | 4.24% | $185.67K | $25.72B | 11.02% | 74 Outperform | |
| Axsome Therapeutics | 4.07% | $177.85K | $7.53B | 51.44% | 55 Neutral | |
| Catalyst Pharma | 3.90% | $170.43K | $2.86B | 8.38% | 83 Outperform | |
| Xenon | 3.65% | $159.47K | $3.18B | 0.02% | 48 Neutral | |
| Centessa Pharmaceuticals | 3.61% | $157.72K | $3.76B | 64.20% | 33 Underperform | |
| Supernus Pharmaceuticals | 3.45% | $151.12K | $2.60B | 25.12% | 55 Neutral |
IBRN Technical Analysis
Positive
―
Price Trends
28.15
Positive
26.04
Positive
24.39
Positive
Market Momentum
0.35
Positive
59.23
Neutral
81.69
Negative
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For IBRN, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 29.33, equal to the 50-day MA of 28.15, and equal to the 200-day MA of 24.39, indicating a bullish trend. The MACD of 0.35 indicates Positive momentum. The RSI at 59.23 is Neutral, neither overbought nor oversold. The STOCH value of 81.69 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IBRN.
IBRN Peer Comparison
Comparison Results
Performance Comparison
IBRN
iShares Neuroscience and Healthcare ETF
29.88
3.52
13.35%
CANC
Tema Oncology ETF
―
―
―
FMED
Fidelity Disruptive Medicine ETF
―
―
―
HRTS
Tema Cardiovascular and Metabolic ETF
―
―
―
OZEM
Roundhill GLP-1 & Weight Loss ETF
―
―
―
PSIL
AdvisorShares Psychedelics ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents